Anticorps Monoclonal anti-PD-L1/CD274

PD-L1/CD274 Monoclonal Antibody for FC

Hôte / Isotype

Rat / IgG2b, kappa

Réactivité testée

souris et plus (1)

Applications

IHC, FC

Conjugaison

Non conjugué

Publications(1)

CloneNo.

10F.9G2

N° de cat : 65073-1-Ig

Synonymes

Cd274, PD-L1, Pdcd1lg1, Pdcd1l1, PD L1



Applications testées

Résultats positifs en cytométrieAnti-CD3/CD28 stimulated mouse splenocytes

Dilution recommandée

ApplicationDilution
This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, check data in validation data gallery

Applications publiées

IHCSee 1 publications below

Informations sur le produit

65073-1-Ig cible PD-L1/CD274 dans les applications de IHC, FC et montre une réactivité avec des échantillons souris

Réactivité souris
Réactivité citéeHumain
Hôte / Isotype Rat / IgG2b, kappa
Clonalité Monoclonal
Type Anticorps
Immunogène s/o
Nom complet CD274 antigen
Numéro d’acquisition GenBankBC066841
Symbole du gène PD-L1
Identification du gène (NCBI) 60533
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Purification par affinité
Tampon de stockage PBS with 0.09% sodium azide
Conditions de stockageStore at 2-8°C. Stable for one year after shipment.

Informations générales

Programmed cell death ligand 1 (PD-L1, CD274, or B7-H1), is the first member of B7 family to be discovered. B7 family molecules are type I transmembrane proteins belonging to the immunoglobulin superfamily. In concert with their CD28 family receptors, the B7s are key regulators of the adaptive immune response. PD-L1 is suggested as a negative regulator of T and B cell, and plays important role in mediating tolerance of lymphocytes to self-antigens. It is also involved in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PD-1-independent manner.

Protocole

Product Specific Protocols
FC protocol for PD-L1/CD274 antibody 65073-1-IgDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
humanIHC

J Transl Med

Immunoproteasome subunits are novel signatures for predicting efficacy of immunotherapy in muscle invasive bladder cancer

Authors - XinJian Wang
{{ptg:RelatedPrimaryAntibodies}}